January 17, 2024
Taisho Pharmaceutical on January 16 launched a subcutaneous autoinjector version of its rheumatoid arthritis (RA) drug Nanozora (ozoralizumab) in Japan. A TNFα inhibitor licensed from Belgium-based Ablynx, Nanozora hit the market in December 2022 in a syringe form for subcutaneous...read more